scholarly journals Fine Mapping of the Friend Retrovirus Resistance Gene, Rfv3, on Mouse Chromosome 15

1999 ◽  
Vol 73 (9) ◽  
pp. 7848-7852 ◽  
Author(s):  
Heidi J. Super ◽  
Kim J. Hasenkrug ◽  
Stacey Simmons ◽  
Diane M. Brooks ◽  
Roberta Konzek ◽  
...  
Keyword(s):  
Microsatellite Markers ◽  
Resistance Gene ◽  
Neutralizing Antibody ◽  
Interspecific Backcross ◽  
Chromosome 15 ◽  
Friend Retrovirus ◽  
Progeny Tests ◽  
First Time ◽  
Gene Maps ◽  
Recombinant Mice

ABSTRACT Rfv3 is a host resistance gene that operates through an unknown mechanism to control the development of the virus-neutralizing antibody response required for recovery from infection with Friend retrovirus. The Rfv3 gene was previously mapped to an approximately 20-centimorgan (cM) region of chromosome 15. More refined mapping was not possible, due to a lack of microsatellite markers and leakiness in the Rfv3 phenotype, which prevented definitive phenotyping of individual recombinant mice. In the present study, we overcame these difficulties by taking advantage of seven new microsatellite markers in the Rfv3 region and by using progeny tests to accurately determine the Rfv3 phenotype of recombinant mice. Detailed linkage analysis of relevant crossovers narrowed the location of Rfv3 to a 0.83-cM region. Mapping of closely linked genes in an interspecific backcross panel allowed us to exclude two previous candidate genes, Ly6 andWnt7b. These studies also showed for the first time that the Hsf1 gene maps to the Rfv3-linked cluster of genes including Il2rb, Il3rb, and Pdgfb. This localization of Rfv3 to a region of less than 1 cM now makes it feasible to attempt the cloning of Rfv3 by physical methods.

Isolation, Characterization, and Mapping of Genomic Microsatellite Markers for the First Time in Sea-Island Cotton (Gossypium barbadense)

2009 ◽  
Vol 35 (6) ◽  
pp. 1013-1020 ◽  
Author(s):  
Pei-Pei ZHANG ◽  
Xia-Qing WANG ◽  
Yang YU ◽  
Yu YU ◽  
Zhong-Xu LIN ◽  
...  
Keyword(s):  
Microsatellite Markers ◽  
Gossypium Barbadense ◽  
First Time

scholarly journals Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

2015 ◽  
Vol 112 (33) ◽  
pp. 10473-10478 ◽  
Author(s):  
Davide Corti ◽  
Jincun Zhao ◽  
Mattia Pedotti ◽  
Luca Simonelli ◽  
Sudhakar Agnihothram ◽  
...  
Keyword(s):  
B Cells ◽  
Neutralizing Antibodies ◽  
Human Monoclonal Antibody ◽  
Infected Individual ◽  
Chinese Hamster ◽  
Neutralizing Antibody ◽  
Emerging Viruses ◽  
Antiviral Therapies ◽  
Human Infections ◽  
First Time

Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a previously unidentified coronavirus (CoV), likely transmitted to humans by infected camels. There is no licensed vaccine or antiviral for MERS, therefore new prophylactic and therapeutic strategies to combat human infections are needed. In this study, we describe, for the first time, to our knowledge, the isolation of a potent MERS-CoV–neutralizing antibody from memory B cells of an infected individual. The antibody, named LCA60, binds to a novel site on the spike protein and potently neutralizes infection of multiple MERS-CoV isolates by interfering with the binding to the cellular receptor CD26. Importantly, using mice transduced with adenovirus expressing human CD26 and infected with MERS-CoV, we show that LCA60 can effectively protect in both prophylactic and postexposure settings. This antibody can be used for prophylaxis, for postexposure prophylaxis of individuals at risk, or for the treatment of human cases of MERS-CoV infection. The fact that it took only 4 mo from the initial screening of B cells derived from a convalescent patient for the development of a stable chinese hamster ovary (CHO) cell line producing neutralizing antibodies at more than 5 g/L provides an example of a rapid pathway toward the generation of effective antiviral therapies against emerging viruses.

scholarly journals Microsatellite markers for the Triticum timopheevi-derived leaf rust resistance gene Lr18 on wheat 5BL chromosome

2017 ◽  
Vol 67 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Ali Aliakbari Sadeghabad ◽  
Ali Dadkhodaie ◽  
Bahram Heidari ◽  
Hooman Razi ◽  
Reza Mostowfizadeh-Ghalamfarsa
Keyword(s):  
Microsatellite Markers ◽  
Leaf Rust ◽  
Resistance Gene ◽  
Rust Resistance ◽  
Leaf Rust Resistance ◽  
Rust Resistance Gene ◽  
Leaf Rust Resistance Gene ◽  
Triticum Timopheevi

scholarly journals A role for IL-34 in osteolytic disease of multiple myeloma

2019 ◽  
Vol 3 (4) ◽  
pp. 541-551 ◽  
Author(s):  
Muhammad Baghdadi ◽  
Kozo Ishikawa ◽  
Sayaka Nakanishi ◽  
Tomoki Murata ◽  
Yui Umeyama ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Osteoclast Differentiation ◽  
Neutralizing Antibody ◽  
Axial Skeleton ◽  
Osteoclast Formation ◽  
Interfering Rna ◽  
First Time ◽  
Stimulating Factor

AbstractMultiple myeloma (MM) is a hematological malignancy that grows in multiple sites of the axial skeleton and causes debilitating osteolytic disease. Interleukin-34 (IL-34) is a newly discovered cytokine that acts as a ligand of colony-stimulating factor-1 (CSF-1) receptor and can replace CSF-1 for osteoclast differentiation. In this study, we identify IL-34 as an osteoclastogenic cytokine that accelerates osteolytic disease in MM. IL-34 was found to be expressed in the murine MM cell line MOPC315.BM, and the expression of IL-34 was enhanced by stimulation with proinflammatory cytokines or by bone marrow (BM) stromal cells. MM-cell–derived IL-34 promoted osteoclast formation from mouse BM cells in vitro. Targeting Il34 by specific small interfering RNA impaired osteoclast formation in vitro and attenuated osteolytic disease in vivo. In BM aspirates from MM patients, the expression levels of IL-34 in CD138+ populations vary among patients from high to weak to absent. MM cell–derived IL-34 promoted osteoclast formation from human CD14+ monocytes, which was reduced by a neutralizing antibody against IL-34. Taken together, this study describes for the first time the expression of IL-34 in MM cells, indicating that it may enhance osteolysis and suggesting IL-34 as a potential therapeutic target to control pathological osteoclastogenesis in MM patients.

Variation in lipid reserves of second-stage juveniles of Meloidogyne exigua in a coffee field and its relationship with infectivity

Nematology ◽  
2010 ◽  
Vol 12 (3) ◽  
pp. 365-371 ◽  
Author(s):  
Fernando da Silva Rocha ◽  
Jorge Teodoro de Souza ◽  
Vicente Paulo Campos
Keyword(s):  
Image Analysis ◽  
Resistance Gene ◽  
Lipid Content ◽  
Neutral Lipids ◽  
Resistance Level ◽  
Annual Variations ◽  
Second Stage ◽  
Tomato Cultivars ◽  
First Time

AbstractIn this study we assessed the variations in lipid content of second-stage juveniles (J2) of Meloidogyne exigua, recovered from a coffee field, by staining and quantifying the neutral lipids using image analysis. Our results showed that annual variations in J2 stained lipid area correlate with temperature, rainfall and total number of J2 per 100 cm3 of soil. Laboratory and glasshouse experiments showed that decreases in the lipid stained area of J2 of M. exigua led to decreased infectivity and reproduction on tomato. The susceptibility of tomato cvs Kada and Nemadoro to M. exigua varied according to the stained lipid area of the J2 inoculated on roots. Only J2 containing an average of 80% stained lipid area were able to infect cv. Nemadoro, which contains the Mi resistance gene, whereas J2 containing 20% stained lipid area were still able to infect cv. Kada, considered to be highly susceptible. In this study we show for the first time the dynamics of lipid variation in J2 of M. exigua in a coffee field and the dependence of infectivity and parasitism on the resistance level of tomato cultivars and the lipid stained area in J2.

scholarly journals Resistance Profiling and Molecular Characterization of Extended-Spectrum/Plasmid-Mediated AmpC β-Lactamase-Producing Escherichia coli Isolated from Healthy Broiler Chickens in South Korea

2020 ◽  
Vol 8 (9) ◽  
pp. 1434 ◽  
Author(s):  
Hyun-Ju Song ◽  
Dong Chan Moon ◽  
Abraham Fikru Mechesso ◽  
Hee Young Kang ◽  
Mi Hyun Kim ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Phylogenetic Analysis ◽  
Resistance Gene ◽  
Broiler Chickens ◽  
Human Consumption ◽  
E Coli ◽  
Extended Spectrum ◽  
First Time ◽  
Pfge Profiles

We aimed to identify and characterize extended-spectrum β-lactamase (ESBL)-and/or plasmid-mediated AmpC β-lactamase (pAmpC)-producing Escherichia coli isolated from healthy broiler chickens slaughtered for human consumption in Korea. A total of 332 E. coli isolates were identified from 339 cloacal swabs in 2019. More than 90% of the isolates were resistant to multiple antimicrobials. ESBL/pAmpC-production was noted in 14% (46/332) of the isolates. Six of the CTX-M-β-lactamase-producing isolates were found to co-harbor at least one plasmid-mediated quinolone resistance gene. We observed the co-existence of blaCMY-2 and mcr-1 genes in the same isolate for the first time in Korea. Phylogenetic analysis demonstrated that the majority of blaCMY-2-carrying isolates belonged to subgroup D. Conjugation confirmed the transferability of blaCTX-M and blaCMY-2 genes, as well as non-β-lactam resistance traits from 60.9% (28/46) of the ESBL/pAmpC-producing isolates to a recipient E. coli J53. The ISECP, IS903, and orf477 elements were detected in the upstream or downstream regions. The blaCTX-M and blaCMY-2 genes mainly belonged to the IncI1, IncHI2, and/or IncFII plasmids. Additionally, the majority of ESBL/pAmpC-producing isolates exhibited heterogeneous PFGE profiles. This study showed that healthy chickens act as reservoirs of ESBL/pAmpC-producing E. coli that can potentially be transmitted to humans.

Mouse natriuretic peptide receptor 3 gene maps to proximal Chromosome 15

1997 ◽  
Vol 8 (10) ◽  
pp. 788-788 ◽  
Author(s):  
Olga V. Savinova ◽  
Naomich Matsukawa ◽  
Oliver Smithies ◽  
Simon W.M. John
Keyword(s):  
Natriuretic Peptide ◽  
Chromosome 15 ◽  
Natriuretic Peptide Receptor ◽  
Peptide Receptor ◽  
Gene Maps

Three bovine chromosome 15 microsatellite markers

2009 ◽  
Vol 26 (2) ◽  
pp. 124-124 ◽  
Author(s):  
J L Williams ◽  
B G Urquhart ◽  
B Barendse
Keyword(s):  
Microsatellite Markers ◽  
Bovine Chromosome ◽  
Chromosome 15

scholarly journals Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2

2020 ◽  
Author(s):  
Raymond T Suhandynata ◽  
Melissa A Hoffman ◽  
Deli Huang ◽  
Jenny T Tran ◽  
Michael J Kelner ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Neutralization Assay ◽  
Positive Serology ◽  
Neutralization Activity ◽  
Antibody Titers ◽  
Negative Controls ◽  
First Time ◽  
The Relationship ◽  
Positive Results

Background. Currently it is unknown whether a positive serology results correlates with protective immunity against SARS-CoV-2. There are also concerns regarding the low positive predictive value of SARS-CoV-2 serology tests, especially when testing populations with low disease prevalence. Methods. A neutralization assay was validated in a set of PCR confirmed positive specimens and in a negative cohort. 9,530 specimens were screened using the Diazyme SARS-CoV-2 IgG serology assay and all positive results (N=164) were reanalyzed using the neutralization assay, the Roche total immunoglobin assay, and the Abbott IgG assay. The relationship between the magnitude of a positive SARS-CoV-2 serology result and the levels of neutralizing antibodies detected was correlated. Neutralizing antibody titers (ID50) were also longitudinally monitored in SARS-CoV-2 PCR confirmed patients. Results. The SARS-CoV-2 neutralization assay had a PPA of 96.6% with a SARS-CoV-2 PCR test and a NPA of 98.0% across 100 negative controls. ID50 neutralization titers positively correlated with all three clinical serology platforms. Longitudinal monitoring of hospitalized PCR confirmed COVID-19 patients demonstrates they made high neutralization titers against SARS-CoV-2. PPA between the Diazyme IgG assay alone and the neutralization assay was 50.6%, while combining the Diazyme IgG assay with either the Roche or Abbott platforms increased the PPA to 79.2% and 78.4%, respectively. Conclusions. For the first time, we demonstrate that three widely available clinical serology assays positively correlate with SARS-CoV-2 neutralization activity observed in COVID-19 patients. When a two-platform screen and confirm approach was used for SARS-CoV-2 serology, nearly 80% of two-platform positive specimens had neutralization titers (ID50 >50).

Sign in / Sign up

Export Citation Format

Share Document